Importantly, the expression of CPT2 was also downregulated in human SH-HCC, and NASH patients with HCC showed increased serum levels of acylcarnitine, suggesting that a similar metabolic change may occur in human obesity-mediated HCC. Here, CPT2 is linked to metabolic dysfunction-associated steatohepatitis.